We are live on ! Find out more
JGUA

John G. Ullman & Associates Portfolio holdings

AUM $754M
1-Year Est. Return 60.05%
This Fund
S&P 500
This Quarter Est. Return
+8.51%
1 Year Est. Return
+60.05%
3 Year Est. Return
+108.28%
5 Year Est. Return
+118.76%
10 Year Est. Return
+308.24%
AUM
$524M
AUM Growth
+$32.8M
Cap. Flow
-$6.68M
Cap. Flow %
-1.28%
Top 10 Hldgs %
32.2%
Holding
157
New
6
Increased
38
Reduced
96
Closed
8

Top Buys

Rank Stock Value
1
IBM icon
IBM
IBM
+$3.58M
2
ITRI icon
Itron
ITRI
+$1.9M
3
LLY icon
Eli Lilly
LLY
+$1.83M
4
LNN icon
Lindsay Corp
LNN
+$1.79M
5
EME icon
Emcor
EME
+$1.22M

Sector Composition

Rank Sector Weight
1 Healthcare 24.97%
2 Industrials 17.47%
3 Technology 16.95%
4 Energy 9%
5 Utilities 8.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
FCX icon
51
Freeport-McMoran
FCX
$91.2B
$2.92M 0.56%
77,425
-1,100
-1% -$39K
DLB icon
52
Dolby
DLB
$4.9B
$2.89M 0.55%
74,850
-2,850
-4% -$102K
MON
53
DELISTED
Monsanto Co
MON
$2.66M 0.51%
22,785
-6,200
-21% -$677K
GE icon
54
GE Aerospace
GE
$368B
$2.64M 0.5%
19,642
+876
+5% +$110K
EWZ icon
55
iShares MSCI Brazil ETF
EWZ
$9.25B
$2.59M 0.49%
57,925
-14,440
-20% -$686K
AMAT icon
56
Applied Materials
AMAT
$398B
$2.54M 0.48%
143,364
+200
+0.1% +$3.48K
JPM icon
57
JPMorgan Chase
JPM
$933B
$2.49M 0.47%
42,532
-234
-0.5% -$12.8K
SR icon
58
Spire
SR
$4.76B
$2.42M 0.46%
53,200
-1,500
-3% -$69K
XYL icon
59
Xylem
XYL
$27.3B
$2.34M 0.45%
67,550
-1,900
-3% -$61.1K
WTS icon
60
Watts Water Technologies
WTS
$11.5B
$2.33M 0.44%
37,589
-500
-1% -$29K
EPU icon
61
iShares MSCI Peru and Global Exposure ETF
EPU
$543M
$2.3M 0.44%
68,300
-33,050
-33% -$1.09M
TT icon
62
Trane Technologies
TT
$97.3B
$2.25M 0.43%
36,510
-6,509
-15% -$359K
TYC
63
DELISTED
TYCO INTL PLC COM SHS (IRL)
TYC
$2.22M 0.42%
51,676
+6,637
+15% +$258K
NEOG icon
64
Neogen
NEOG
$2.51B
$2.12M 0.41%
123,963
-3,713
-3% -$64.6K
EEM icon
65
iShares MSCI Emerging Markets ETF
EEM
$28.6B
$2.07M 0.39%
49,450
+28,100
+132% +$1.18M
IAF
66
abrdn Australia Equity Fund
IAF
$124M
$2.01M 0.38%
79,304
-25,953
-25% -$775K
MENT
67
DELISTED
Mentor Graphics Corp
MENT
$2M 0.38%
83,200
-8,900
-10% -$201K
ABT icon
68
Abbott
ABT
$183B
$1.98M 0.38%
51,747
+14,025
+37% +$517K
AGX icon
69
Argan
AGX
$8.13B
$1.97M 0.38%
71,617
-1,300
-2% -$30.4K
EWC icon
70
iShares MSCI Canada ETF
EWC
$6.17B
$1.97M 0.38%
67,560
-1,400
-2% -$40.5K
VALE icon
71
Vale
VALE
$63.8B
$1.97M 0.38%
128,950
+30,500
+31% +$474K
CGW icon
72
Invesco S&P Global Water Index ETF
CGW
$1.05B
$1.95M 0.37%
70,500
-1,200
-2% -$31.8K
STJ
73
DELISTED
St Jude Medical
STJ
$1.91M 0.36%
30,799
-400
-1% -$23.2K
AEGN
74
DELISTED
Aegion Corp
AEGN
$1.87M 0.36%
85,450
+7,500
+10% +$163K
EWA icon
75
iShares MSCI Australia ETF
EWA
$1.41B
$1.85M 0.35%
76,000
+20,050
+36% +$513K

Similar funds

John G. Ullman & Associates's Q4 2013 Portfolio in Review

As of Q4 2013, John G. Ullman & Associates held 157 positions worth $524M, up 6.7% from $491M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

John G. Ullman & Associates's Q4 2013 filing shows 6 new, 38 increased, 96 reduced and 8 closed positions. Its largest new stake was Emcor: 31,300 shares worth $1.33M. The largest sale was Bristol-Myers Squibb, an estimated $2.98M.

By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 25% a quarter earlier, followed by Industrials and Technology.

  • John G. Ullman & Associates's largest Q4 2013 buy was Emcor: 31,300 shares worth $1.33M.
  • John G. Ullman & Associates added most to IBM in Q4 2013, an estimated $3.58M increase.
  • John G. Ullman & Associates's biggest Q4 2013 reduction was Bristol-Myers Squibb, cutting an estimated $2.98M.
  • John G. Ullman & Associates fully exited Darling Ingredients in Q4 2013, selling an estimated $1.65M.
  • John G. Ullman & Associates's ten largest holdings make up 32% of its $524M portfolio in Q4 2013.
  • John G. Ullman & Associates opened 6 new positions and closed 8 in Q4 2013.
  • John G. Ullman & Associates's portfolio value rose 6.7% quarter-over-quarter to $524M.

Based on John G. Ullman & Associates's 13F filing for Q4 2013, filed 3 Feb 2014.